CATALOGO DEI PRODOTTI DELLA RICERCA

FRACASSO, Giulio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.719
EU - Europa 3.475
AS - Asia 2.935
SA - Sud America 423
AF - Africa 41
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 5
Totale 11.603
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.630
GB - Regno Unito 1.214
SG - Singapore 1.096
CN - Cina 1.060
BR - Brasile 379
IT - Italia 357
HK - Hong Kong 339
SE - Svezia 317
FR - Francia 306
IE - Irlanda 293
RU - Federazione Russa 266
DE - Germania 256
FI - Finlandia 229
VN - Vietnam 99
KR - Corea 97
UA - Ucraina 76
CA - Canada 51
TR - Turchia 45
ID - Indonesia 30
BE - Belgio 29
IN - India 29
NL - Olanda 29
JP - Giappone 28
MX - Messico 28
IR - Iran 22
PL - Polonia 21
ES - Italia 16
BD - Bangladesh 15
IQ - Iraq 13
ZA - Sudafrica 13
AR - Argentina 11
AT - Austria 11
EC - Ecuador 9
PK - Pakistan 8
AE - Emirati Arabi Uniti 7
CH - Svizzera 7
AZ - Azerbaigian 5
GR - Grecia 5
MA - Marocco 5
PE - Perù 5
PH - Filippine 5
PT - Portogallo 5
UY - Uruguay 5
UZ - Uzbekistan 5
BY - Bielorussia 4
CL - Cile 4
CO - Colombia 4
DZ - Algeria 4
EG - Egitto 4
HR - Croazia 4
JO - Giordania 4
LV - Lettonia 4
PA - Panama 4
TW - Taiwan 4
VE - Venezuela 4
AU - Australia 3
DK - Danimarca 3
EU - Europa 3
HN - Honduras 3
KW - Kuwait 3
LT - Lituania 3
LU - Lussemburgo 3
TG - Togo 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
CM - Camerun 2
CY - Cipro 2
CZ - Repubblica Ceca 2
IL - Israele 2
KE - Kenya 2
KG - Kirghizistan 2
NO - Norvegia 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BJ - Benin 1
BO - Bolivia 1
BT - Bhutan 1
BW - Botswana 1
CI - Costa d'Avorio 1
ET - Etiopia 1
GM - Gambi 1
GT - Guatemala 1
HU - Ungheria 1
IM - Isola di Man 1
IS - Islanda 1
JM - Giamaica 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
ME - Montenegro 1
MR - Mauritania 1
MY - Malesia 1
NP - Nepal 1
OM - Oman 1
Totale 11.593
Salva come PNG Salva come JPEG
Città #
Southend 1.073
Chandler 644
Dallas 624
Jacksonville 563
Singapore 494
Woodbridge 408
Hong Kong 329
Dublin 290
Ann Arbor 281
Ashburn 243
Houston 203
Beijing 196
Verona 142
Lawrence 106
Princeton 106
Wilmington 100
Jinan 91
Nanjing 79
New York 66
Shenyang 64
Los Angeles 57
Buffalo 56
Helsinki 56
The Dalles 54
Tianjin 52
Hebei 49
Changsha 42
Columbus 42
Munich 41
Sindelfingen 39
Zhengzhou 37
Seoul 36
Dong Ket 35
São Paulo 33
Milan 31
Santa Clara 31
Seattle 31
Boardman 29
Brussels 29
Redondo Beach 28
Jakarta 26
Tokyo 26
Guangzhou 25
Haikou 25
Ningbo 25
Hangzhou 24
Jiaxing 24
Redwood City 23
Taizhou 22
San Francisco 21
Taiyuan 21
Turku 20
Nanchang 19
Norwalk 18
Lancaster 17
Fuzhou 16
Warsaw 16
Stockholm 15
Council Bluffs 14
Ho Chi Minh City 14
Redmond 14
London 13
Montréal 13
Padova 13
Bologna 12
Brooklyn 12
Frankfurt am Main 12
Moscow 12
Nuremberg 12
Rio de Janeiro 12
Chicago 10
Hanoi 10
Johannesburg 10
Montreal 10
Atlanta 9
Falkenstein 9
Phoenix 9
Amsterdam 8
Belo Horizonte 8
Boston 8
Paris 8
Tehran 8
Brasília 7
Curitiba 7
Denver 7
Kent 7
Lanzhou 7
Mexico City 7
Shanghai 7
Charlotte 6
Chennai 6
Goiânia 6
Guayaquil 6
Ipatinga 6
Toronto 6
Washington 6
Ankara 5
Baku 5
Campinas 5
Elora 5
Totale 7.664
Salva come PNG Salva come JPEG
Nome #
Anti PSMA immunotoxins activity against prostate cancer cell lines. 198
Immunotoxins and other conjugates: preparation and general characteristics. 179
Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. 171
Anti-PSMA-Immunotoxins: a new therapeutical strategy for selective targeting of toxins to prostate cancer cells. 161
Anti PSCA Monoclonal Antibody and scFv-Fragment for Immunotherapy of Prostate, Pancreatic and Bladder Carcinoma 159
Reductive activation of ricin and ricin-A chain immunotoxins by Protein Disulfide Isomerase and Thioredoxin Reductase system. 155
Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing. 155
Filamin A-mediated interaction of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin regulates survival of advanced prostate cancer cells 155
Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies 155
A SERRS/MRI multimodal contrast agent based on naked Au nanoparticles functionalized with a Gd(iii) loaded PEG polymer for tumor imaging and localized hyperthermia 153
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer 152
A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin 149
Targeted Killing of Prostate Cancer Cells using Antibody-Drug conjugated Carbon Nanohorns 146
Cooperation of Prostate Specific Membrane Antigen with beta 1 integrin promotes the survival of aggressive prostate cancer cells 145
Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo" 145
Characterization of a new anti PSCA monoclonal antibody and scFv fragment for diagnosis and immunotherapy of prostate, pancreatic and bladder carcinoma. 143
Anti-prostate specific membrane antigen targeted gold nanoparticles in tumor therapy and diagnosis 142
Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi 141
Biodistribution of In-111-labeled D2B IgG, F(ab’)2 and Fab fragments in nude mice bearing human prostate cancer xenografts 137
EpCAM a possible target for immunotoxin treatments of PSMA positive and negative prostate cancer cells 136
Characterization of In-111-labeled site-specifically conjugated anti-PSMA antibody-drug conjugates for treatment of PSMA-expressing tumors 134
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumor cells by activating the MAPK pathways. 134
N-terminal deletion affetcs catalytic activity of saporin toxin. 133
The prostate specific membrane antigen regulates the expression of IL-6 and CCL-5 in prostate tumour cells by activating the MAPK pathways 133
Production of a biotinylated anti-PSMA single-chain antibody fragment (scFv) for imaging and radioimmunotherapy 131
Investigation of Properties of Anti-Prostate Specific Membrane Antigen-targeted Gold Nanoparticles as Drug Carriers in Tumor Therapy 131
Produzione e validazione preclinica di un anticorpo anti-PSMA per diagnostica ed immunotargeting 131
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 130
Protein Disulfide Isomerase and Thioredoxin Reductase: a ricin disulfide reducing system in the endoplasmic reticulum. 129
Targeted delivery of photosensitizers: efficacy and selectivity issues revealed by multifunctional ORMOSIL nanovectors in cellular systems 129
Plasmonic Nanostructures for SERRS Multiplexed Identification of Tumor-Associated Antigens 126
Prostate-specific membrane antigen associates already in the endoplasmic reticulum with lipid microdomains 125
Constitutive activation of p38 and ERK1/2 MAPKs in epithelial cells of myasthenic thymus leads to IL-6 and RANTES overexpression: effects on survival and migration of peripheral T and B cells. 124
Ingegnerizzazione di un vettore per espressione di frammenti anticorpali (scFv) biotinilati in procarioti, purificazione ed analisi funzionale 124
Reductive activation of ricin and ricin A-chain immunotoxins by protein disulfide isomerase and thioredoxin reductase. 121
Tumor Targeting with Guided Silica Nanopartilces for Prostate Cancer Therapy 119
Prostate-specific membrane antigen (PSMA) associates early in the endoplasmic reticulum with lipid microdomains 118
Acute sarcomeric M-Line Disease associated with ATP synthase subunit α autoantibodies in ankylosing spondylitis 118
Discriminatory role of detergent-resistant membranes in the dimerization and endocytosis of prostate-specific membrane antigen 117
The Filamin A-mediated cooperation of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin promotes the survival of aggressive prostate cancer cells. 116
Parallel optical read-out of micromechanical pillars applied to prostate specific membrane antigen detection 115
Top-down synthesis of multifunctional iron oxide nanoparticles for macrophage labelling and manipulation 115
Identification of Ricin A chain HLA II-restricted epitopes by human T-cell clones. 114
Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof 110
Magneto-Plasmonic Au-Fe alloy nanoparticles designed for multimodal SERS-MRI-CT imaging 110
Highly sensitive electrochemiluminescence detection of a prostate cancer biomarker 110
Design and Evaluation of 223Ra-Labeled and Anti-{PSMA} Targeted {NaA} Nanozeolites for Prostate Cancer Therapy{ extendash}Part I 110
Targeting human prostate cancer with (111) In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts. 109
Expression of myelin basic protein (MBP) epitopes in human non-neural cells revealed by two anti-MBP IgM monoclonal antibodies 109
Generazione di nuovi anticorpi anti prostate stem cell antigen (PSCA) e loro caratterizzazione al fine di un futuro utilizzo nella terapia e nella diagnosi dei carcinomi prostatico, pancreatico e della vescica 109
Cloning and characterisation of canine prostate-specific membrane antigen 109
An electrochemiluminescent-supramolecular approach to sarcosine detection for early diagnosis of prostate cancer. 108
Self-potentiation of ligand-toxin conjugates containing ricin A chain fused with viral structures 108
Effect of therapeutic macromolecules in spheroids 107
Prostate Specific Membrane Antigen (PSMA) associates with Filamin A, beta1 integrin, pp130CAS and pSrc thus regulating the activation of beta1 integrin and the survival of prostate cancer cells. 107
Gangliosides act as onconeural antigens in paraneoplastic neuropathies. 106
Pegylated silica nanoparticles: cytotoxicity and macrophage uptake 105
Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors 105
Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin 104
Characterization of an In-111-labeled anti-PSMA antibody-photosensitizer conjugate for targeted photodynamic therapy of PSMA-expressing tumors 103
Laser generated gold nanocorals with broadband plasmon absorption for photothermal applications 100
Neutralization of NET-associated human ARG1 enhances cancer immunotherapy 99
In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe 98
Pharmacokinetics of intrathecal transferrin-ricin A chain immunotoxins 97
SERS IMAGING OF CANCER CELLS WITH ANTIBODY FUNCTIONALIZED GOLD NANOPARTICLES 97
Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells 97
Therapeutic Efficacy of the Novel Stimuli-Sensitive Nano-Ferritins Containing Doxorubicin in a Head and Neck Cancer Model 97
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models 95
Targeted Silica Nanoparticles for PhotoDynamic Therapy (PDT) 91
Improved method for carbohydrate-deficient transferrin determination in human serum by capillary zone electrophoresis 90
Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer 90
Prostate-specific membrane antigen routing to the cell surface implicates an early association step in the endoplasmic reticulum with lipid microdomains. 89
Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA) 88
Polymer-coated silver-iron nanoparticles as efficient and biodegradable MRI contrast agents 88
SERS labels for quantitative assays: application to the quantification of gold nanoparticles uptaken by macrophage cells 87
Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones 86
Different Glycoforms of Prostate-Specific Membrane Antigen are intracellularly transported through their Association with Distinct Detergent-Resistant Membranes 83
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma 83
Design and Evaluation of 223Ra-Labeled and Anti-{PSMA} Targeted {NaA} Nanozeolites for Prostate Cancer Therapy{ extemdash}Part {II}. Toxicity, Pharmacokinetics and Biodistribution 82
Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness 81
Efficient AuFeOx Nanoclusters of Laser-Ablated Nanoparticles in Water for Cells Guiding and Surface-Enhanced Resonance Raman Scattering Imaging 80
Immunology of RIPs and their Immunotoxins, in Ribosome-inactivating Proteins: Ricin and Related Proteins 80
Mitoxantrone-loaded nanoferritin slows tumor growth and improves the overall survival rate in a subcutaneous pancreatic cancer mouse model 80
Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen 79
The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity 78
High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors 78
Simple and Rapid Non-Enzymatic Procedure Allows the Isolation of Structurally Preserved Connective Tissue Micro-Fragments Enriched with SVF 76
Ribosome-inactivating protein-containing conjugates for therapeutic use 75
Safe Core-Satellite Magneto-Plasmonic Nanostructures for Efficient Targeting and Photothermal Treatment of Tumor Cells 75
New Tc-99m-radioimmunoconjugates for pancreatic carcinoma detection 74
Dual modality imaging of PSMA-expressing prostate cancer with a new radiolabeled anti-PSMA monoclonal antibody conjugated with IRDye800CW 74
Improved doxorubicin encapsulation and pharmacokinetics of ferritin-fusion protein nanocarriers bearing proline, serine, and alanine elements 74
SERRS Multiplexing with Multivalent Nanostructures for the Identification and Enumeration of Epithelial and Mesenchymal Cells 74
D2B antibody and its scFvD2B fragment in nanomedicine: promising tools in the theranostics of prostate cancer 72
Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging 71
Targeting prostate cancer cells with D2B-gold Nanoparticles 71
null 70
Engineered Human Nanoferritin Bearing the Drug Genz-644282 for Cancer Therapy 69
Genetic grafting of membrane-acting peptides to the cytotoxin dianthin augments its ability to de-stabilize lipid bilayers and enhances its cytotoxic potential as the component of transferrin-toxin conjugates. 68
Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen 65
Totale 11.074
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.289
article - articoli 32.019
book - libri 0
conference - conferenze 9.835
curatela - curatele 0
other - altro 0
patent - brevetti 747
selected - selezionate 0
volume - volumi 688
Totale 86.578
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021631 0 0 0 95 113 101 21 66 52 20 97 66
2021/2022884 79 250 14 81 37 18 16 51 20 33 74 211
2022/20231.892 147 181 171 322 136 457 74 130 200 13 46 15
2023/2024898 43 85 91 94 109 122 35 55 12 79 123 50
2024/20252.436 113 153 61 367 169 82 123 112 403 186 223 444
2025/20261.642 506 447 618 71 0 0 0 0 0 0 0 0
Totale 11.720